Pfizer has opened applications for its Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata 2026. Interested applicants are encouraged to click here to learn more about this opportunity and apply for it.
The Pfizer Research Grant Request for Proposals (RFP) is designed to support independent research that generates real-world evidence (RWE) on the effectiveness of early initiation of ritlecitinib in treating alopecia areata.The programme seeks to determine whether starting treatment earlier in the disease course leads to improved clinical outcomes compared with delayed treatment or conventional treatment pathways. The findings are expected to enhance understanding of treatment timing and inform future clinical decision-making.
Grant Amount
Applicants may request funding of up to:
USD 100,000 per project
Principal Investigator Requirements
The Principal Investigator (PI) must:
Acceptable qualifications include:
Organizational Requirements
The requesting organization must:
Independent medical practice groups and individual applicants are not eligible.
Apply for Pfizer - Investigating the Benefit of Early Treatment with Ritlecitinib in Alopecia Areata
Need help with your application?
